H. Perry Fell
Directeur/Membre du Conseil chez Prevencio, Inc.
Provenance du réseau au premier degré de H. Perry Fell
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
17
| Subsidiary | Pharmaceuticals: Major | 17 |
Prevencio, Inc.
 Prevencio, Inc. Medical SpecialtiesHealth Technology Prevencio, Inc. operates as a life science company. It is a pioneer in multi-protein in vitro diagnostic (IVD) and prognostic tests for cardiovascular disease for use in Emergency Rooms (ER), cardiology clinics, and clinical laboratories. The company was founded by William A. LaFramboise and is headquartered in Kirkland, WA.
5
| Private Company | Medical Specialties | 5 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à H. Perry Fell via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Rochester Christian University | College/University | Doctorate Degree Undergraduate Degree | |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Investment Managers | Founder | |
| GENOMIC HEALTH, INC. | Medical Specialties | Director/Board Member Chief Tech/Sci/R&D Officer | |
| STEMLINE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| BIO-PATH HOLDINGS, INC. | Biotechnology | Director/Board Member | |
| IMMUNOME, INC. | Biotechnology | Chief Executive Officer | |
| ULTRAGENYX PHARMACEUTICAL INC. | Pharmaceuticals: Major | Director/Board Member | |
| NURIX THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Stanford University | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| Yale University | College/University | Doctorate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree | |
| Princeton University | College/University | Undergraduate Degree | |
| University of Michigan | College/University | Corporate Officer/Principal | |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Director/Board Member Founder | |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
Alpha Omega Alpha Honor Medical Society
 Alpha Omega Alpha Honor Medical Society Miscellaneous Commercial ServicesCommercial Services Alpha Omega Alpha Honor Medical Society is a national medical honor society founded in 1902. The non-profit company is based in Menlo Park, CA. The society's mission is to foster the development of the next generation of medical researchers by recognizing high educational achievement, honoring gifted teaching, encouraging the development of leaders in academia and the community, and supporting the improvement of care for all. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Washington Roundtable
 Washington Roundtable Miscellaneous Commercial ServicesCommercial Services Washington Roundtable works to affect positive change on public policy issues that are most important to supporting state economic vitality and fostering opportunity. Its work includes sharing news and analysing policy developments. The company was founded in 1983 and is headquartered in Seattle, WA. | Miscellaneous Commercial Services | Director/Board Member | |
| Washington Biotechnology & Biomedical Association | Director/Board Member Director/Board Member | ||
| ALDER BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member | |
| Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | ||
The Pacific Northwest Research Institute, Inc.
 The Pacific Northwest Research Institute, Inc. Miscellaneous Commercial ServicesCommercial Services The Pacific Northwest Research Institute, Inc. is a non-profit organization, which engages in the biomedical research. The interests of the Institute’s investigators range from genetic and genomic studies on the cellular and metabolic processes that lead to cancer and neurological defects to foundational and clinical studies on pancreatic function and diabetes. The company was founded by William Hutchinson in 1956 and is headquartered in Seattle, WA. | Miscellaneous Commercial Services | Director/Board Member | |
| Berkeley Law University of California | College/University | Graduate Degree | |
| The University of Miami Leonard M. Miller School of Medicine | College/University | Corporate Officer/Principal | |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Biotechnology | Director/Board Member | |
| Sylvester Comprehensive Cancer Center | Corporate Officer/Principal | ||
| SHATTUCK LABS, INC. | Biotechnology | Director/Board Member | |
Aurora Biopharma, Inc.
 Aurora Biopharma, Inc. BiotechnologyHealth Technology Aurora Biopharma, Inc. develops Chimeric Antigen Receptor (CAR) T therapy, cancer vaccines, and combinations with checkpoint Inhibitors services. It develops Aurora’s “Bionic” T Cells : CAR T-Cells engineered to kill cancer and Aurora’s Revolutionary CAR T cell Clinical Cancer Trials. The company was founded by Robert Brooks and Marc Lippman and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
| Lombardi Cancer Research Center | Director/Board Member | ||
Georgetown Lombardi Comprehensive Cancer Center
 Georgetown Lombardi Comprehensive Cancer Center Hospital/Nursing ManagementHealth Services Georgetown Lombardi Comprehensive Cancer Center is a comprehensive cancer center designated by the National Cancer Institute (NCI) and is a part of Georgetown University Medical Center. It is located in Washington, D.C. and is supported in part by a National Cancer Institute Cancer Center Support Grant. It is the only comprehensive cancer center in the area and serves as the research engine for MedStar Health, Georgetown University’s clinical partner. Georgetown Lombardi seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic, translational, and clinical research, patient care, and community education and outreach. Georgetown Lombardi also offers a master’s degree program in cancer biology, prevention, and control in partnership with the University of the District of Columbia (UDC). | Hospital/Nursing Management | Corporate Officer/Principal | |
Chinook Therapeutics U.S., Inc.
 Chinook Therapeutics U.S., Inc. Information Technology ServicesTechnology Services Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA. | Information Technology Services | Director/Board Member Chief Executive Officer | |
| STRUCTURE THERAPEUTICS INC. | Miscellaneous Commercial Services | Director/Board Member | |
Umoja Biopharma, Inc.
 Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Chairman | |
| CHINOOK THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer General Counsel | |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Biotechnology | Chief Executive Officer | |
Alphageneron Pharmaceuticals, Inc.
 Alphageneron Pharmaceuticals, Inc. BiotechnologyHealth Technology Alphageneron Pharmaceuticals, Inc. is a biotechnology company that specializes in developing antibody drug conjugates and natural killer. The company is based in Cambridge, MA. The company was founded by Robert K. Brooks and he has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Miscellaneous Commercial Services | Chairman | |
| ATARA BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 49 |
| Canada | 2 |
Sectorielle
| Health Technology | 25 |
| Commercial Services | 10 |
| Consumer Services | 9 |
| Finance | 2 |
| Miscellaneous | 2 |
Opérationnelle
| Director/Board Member | 136 |
| Corporate Officer/Principal | 54 |
| Independent Dir/Board Member | 46 |
| Chief Tech/Sci/R&D Officer | 19 |
| Undergraduate Degree | 17 |
Relations les plus connectées
| Insiders | |
|---|---|
| Srini Akkaraju Akkaraju | 54 |
| Felix Baker | 28 |
| Louis C. Bock | 27 |
| Douglas Williams | 25 |
| Clay Siegall | 18 |
| Marc Lippman | 14 |
| Eric Dobmeier | 14 |
| Andrew Sandler | 12 |
| Peter D. Senter | 8 |
| Kirk D. Schumacher | 6 |
| Michael McDonald | 6 |
| Larry K. Benedict | 6 |
| Paul J. Carter | 5 |
| Alan F. Wahl | 5 |
| Amy P. Sing | 5 |
- Bourse
- Insiders
- H. Perry Fell
- Connexions Sociétés
